^
ETV6-NTRK3 fusion
Salivary Gland Cancer
larotrectinib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
HER-2 positive
Salivary Gland Cancer
trastuzumab
Sensitive
:
A1
No biomarker
Salivary Gland Cancer
cisplatin + doxorubicin hydrochloride + cyclophosphamide
Sensitive
:
A2
No biomarker
Salivary Gland Cancer
cisplatin + vinorelbine tartrate
Sensitive
:
A2
NTRK2 fusion
Salivary Gland Cancer
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Salivary Gland Cancer
larotrectinib
Sensitive
:
A2
NTRK3 fusion
Salivary Gland Cancer
larotrectinib
Sensitive
:
A2
NTRK3 fusion
Salivary Gland Cancer
entrectinib
Sensitive
:
A2
NTRK1 fusion
Salivary Gland Cancer
entrectinib
Sensitive
:
A2
NTRK2 fusion
Salivary Gland Cancer
entrectinib
Sensitive
:
A2
AR positive
Salivary Gland Cancer
leuprolide acetate
Sensitive
:
A2
AR positive
Salivary Gland Cancer
bicalutamide
Sensitive
:
A2
HER-2 positive
Salivary Gland Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A2
No biomarker
Salivary Gland Cancer
carboplatin + gemcitabine
Sensitive
:
A2
No biomarker
Salivary Gland Cancer
carboplatin + paclitaxel
Sensitive
:
A2
No biomarker
Salivary Gland Cancer
paclitaxel
Sensitive
:
A2
PD-L1 expression
Salivary Gland Cancer
pembrolizumab
Sensitive
:
C1
HER-2 overexpression
Salivary Gland Cancer
trastuzumab
Sensitive
:
C1
RET fusion
Salivary Gland Cancer
selpercatinib
Sensitive
:
C1
RET fusion
Salivary Gland Cancer
pralsetinib
Sensitive
:
C1
HER-2 positive
Salivary Gland Cancer
trastuzumab-pkrb
Sensitive
:
C1
HER-2 overexpression
Salivary Gland Cancer
trastuzumab
Sensitive
:
C2
HER-2 amplification
Salivary Gland Cancer
ado-trastuzumab emtansine
Sensitive
:
C2
HER-2 amplification
Salivary Gland Cancer
trastuzumab
Sensitive
:
C2
AR positive
Salivary Gland Cancer
leuprolide acetate + bicalutamide
Sensitive
:
C3
PLIN2 expression
Salivary Gland Cancer
leuprolide acetate + bicalutamide
Sensitive
:
C3
AKT1 E17K
Salivary Gland Cancer
AZD5363
Sensitive
:
C3
HER-2 expression
Salivary Gland Cancer
ARX788
Sensitive
:
C3
HRAS mutation
Salivary Gland Cancer
tipifarnib
Sensitive
:
C3
HER-2 amplification
Salivary Gland Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C3
HER-2 expression
Salivary Gland Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C3
PTEN expression
Salivary Gland Cancer
bicalutamide
Sensitive
:
C3
PTEN expression
Salivary Gland Cancer
trastuzumab
Sensitive
:
C3